Figure 3C-D shows that a median of 16.5% CD4+ and 31.2% CD8+ BM-resident T cells from AML patients produced IFN-γ, respectively, and suggests that intra-tumoral T cells can be an in vivo source of this cytokine in AML. This evidence concerns the gene IFNG and acute myeloid leukemia.